gsk

GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences

GSK plc (LSE/NYSE: GSK) today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held ...
gsk

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer

Results support potential to address key efficacy and tolerability needs in ROS1-positive NSCLC with US regulatory submission planned in 2026 GSK plc (LSE/NYSE: GSK) today announced positive results ...
gsk

GSK files regulatory submission in the EU for a next-generation, lower-carbon version of Ventolin (salbutamol) metered dose inhaler

GSK has submitted a regulatory application in the European Union for a next-generation lower-carbon version of its Ventolin (salbutamol) metered dose inhaler (MDI). The submission is supported by ...
gsk

GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data

GSK plc (LSE/NYSE: GSK) presented positive phase II data for its mRNA seasonal influenza (flu) vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza. GSK’s vaccine candidate ...